All lobbying filings

THE MCMANUS GROUP

Lobbying for ROYAL BIOLOGICS · OrthoBiologics and life science company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 5768
Skin Substitute Access and Payment Reform Act
S 2561
Skin Substitute Access and Payment Reform Act of 2025
HR 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Lobbying activity 1

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.